Phage Corporate Activity

AmpliPhi Biosciences

 BREAKING NEWS: AmpliPhi Biosciences and C3J Therapeutics 
Merger looks to create bacteriophages to counter antibiotic resistance

14-May-2019 By Maggie Lynch, AmpliPhi Biosciences and C3J Therapeutics merge to focus on the development of phage-based therapeutic candidates for antibiotic resistance. CLICK HERE FOR FULL STORY AmpliPhi Biosciences (NYSE American: APHB) is a clinical-stage biotechnology company focused on the development of bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. Antibiotic resistance is a major global challenge to human health as the incidence of antibiotic-resistant infections continues to increase, resulting in seemingly harmless infections causing serious morbidity or even death.

“A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child’s scratched knee could once again kill.”

Dr. Margaret Chan, WHO’s Director General, 2014

Ampliphibio believe that phage therapeutics are uniquely positioned to address the serious threat of antibiotic-resistance. They can be precisely targeted to kill select bacteria, have a mechanism of action distinct from those of antibiotics, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics, and have been shown to restore antibiotic sensitivity to drug-resistant bacteria.  Their lead development programs target the World Health Organization’s (WHO’s) “Priority Pathogens”.

AmpliPhi collaborates with UCSD to help a 65 yr-old heart patient, Joel Grimwood, who was in dire need. Joel had been suffering from multiple serious infections for 3 years.

>University of Leicester Announce a potential for phage treatment of C-diff infection

Published on 15 June 2015. A specialist team of scientists, including Dr Martha Clokie, from the University of Leicester has isolated viruses that eat bacteria – called phages - to specifically target the highly infectious hospital superbug Clostridium difficile (C. diff).  Now an exciting new collaboration between the University of Leicester, the University of Glasgow and AmpliPhi Biosciences Corporation could lead to the use of bacteriophages for treating the superbug Clostridium difficile infections. Dr Clokie has spent time at the Elieva Institute of bacteriophages, Georgia.


PhagoMed Biopharma GmbH

Viruses have a bad reputation — but some might just be the weapon we need to help in the fight against superbugs. While many viruses do cause deadly diseases, others can actually help cure them, he says — and they’re called phages. More formally known as bacteriophages, these viruses hunt, infect and kill bacteria with deadly selectivity. Whereas antibiotics inhibit the growth of broad range of bacteria - sometimes good bacteria, like you find in the gut - phages target specific strains. Belcredi’s team has estimated that we have at least ten billion phages on each hand, infecting the bacteria that accumulate there.

>Proactive Investors Interview with Alexander Belcredi

Published 8 January 2019. CEO Alexander Belcredi sat down with Christine Corrado with Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.  The privately-held biotech specializes in developing therapeutics uses for phage therapy, which uses lytic bacteriophages, a virus that infects bacteria, to treat multidrug resistant bacterial infections.

>How a long forgotten virus could help us solve the antibiotics crisis.

November 2018: Ted Talk by Alexander Belcredi, CEO PhagoMed Biopharma. He spent nine years at BCG where he was part of the global health care team, focusing on pharma and medtech. He became acutely aware of the urgent need to develop alternatives to antibiotics and was fascinated by the role that phage therapy can play. In 2017, he co-founded PhagoMed Biopharma GmbH, as a biotech company to develop phage-based pharmaceuticals to treat bacterial infections.